- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sequencing of Immunotherapy in Melanoma
During this segment, Richard W. Joseph, MD, discusses the recent approval of the oncolytic agents pembrolizumab and nivolumab for the treatment of metastatic melanoma and his expectations for a combination agent of ipilimumab and nivolumab that is currently pending approval.
Dr Joseph explains that even with a higher level of toxicity, this new combination therapy option is likely to become a front-line treatment option because its benefits are likely to outweigh its risks. However, there may still be certain patients who are not appropriate candidates for combination therapy, he remarks.
“What’s going to be interesting is how to place these [single-agent therapies vs combination therapy] in the right order,” says Dr Joseph.
To help determine the proper sequence of therapy, additional clinical studies and collaboration with the National Comprehensive Cancer Network will be important, he advises.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
